101. |
Merck WO112217 (2008). |
102. |
Merc k & Co. Inc. WO145957 (2007). |
103. |
Merck WO155156 (2009). |
104. |
Merck WO156726 (2008). |
105. |
Merck WO011375 (2010). |
106. |
Merck WO075830 (2009). |
107. |
Merck WO 2010000364 (2010) |
108. |
Merck WO076316 (2011). |
109. |
Merck WO076327 (2011). |
110. |
Merck WO017047 (2010). |
111. |
Merck WO065384 (2010). |
112. |
Sunesis Pharmaceuticals WO005457 (2008). |
113. |
Merck WO127754 (2010). |
114. |
Merck & Co. WO054941 (2009). |
115. |
Merck WO006567 (2011). |
116. |
Boehringer Ingelheim WO107444 (2008). |
117. |
Boehringer Ingelheim WO007114 (2010). |
118. |
Boehringer Ingelheim WO007116 (2010). |
119. |
Schering AG US07105563 (2006). |
120. |
GlaxoSmithKline WO019637 (2010). |
121. |
GlaxoSmithKline WO059658 (2010). |
122. |
GlaxoSmithKline WO120854 (2010). |
123. |
Novartis Vaccines & Diagnostics Inc. WO117607 (2007). |
124. |
Novartis WO153313 (2009). |
125. |
Novartis WO079988 (2008). |
126. |
Sunesis & Biogen WO044157 (2011). |
127. |
Wyeth WO109599 (2008). |
128. |
Wyeth WO109613 (2008). |
129. |
The Ohio State University Research Foundation US0111799 (2009). |
130. |
Universities of London and Bath WO064559 (2011). |
131. |
Eli Lilly and Co. 041953 (2005). |
132. |
AstraZeneca UK Ltd. WO106326 (2006). |
133. |
Schering AG US0186118A1 (2004). |
134. |
Boehringer Ingelheim Intl. GmbH WO003766 (2008). |
135. |
OSI Pharmaceuticals Inc. WO084667 (2007). |
136. |
Merck Patent GmbH WO079826 (2007). |
137. |
Novartis AG-054238 (2008). |
138. |
Novartis AG WO034600 (2008). |
139. |
SGX Pharmaceuticals Inc. WO015124 (2006). |
140. |
IRM LLC, The Scripps Research Institute WO093812 (2004). |
141. |
Vernalis Cambridge Ltd. WO087707 (2004). |
142. |
Vernalis Cambridge Ltd. WO108136 (2004). |
143. |
Vernalis R&D Ltd. WO134318 (2006). |
144. |
Vertex Pharmaceuticals Inc. WO064397 (2003). |
145. |
Vertex Pharmaceuticals Inc. WO046120 (2004). |
146. |
Vertex Pharmaceuticals WO050249 (2006). |
147. |
Wyeth US0135429 (2007). |
148. |
Phosphosites GmbH EP-1486488-A1 (2004). |